Oppenheimer & CO Inc Neurocrine Biosciences Inc Transaction History
Oppenheimer & CO Inc
- $6.18 Billion
- Q2 2024
A detailed history of Oppenheimer & CO Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Oppenheimer & CO Inc holds 17,238 shares of NBIX stock, worth $2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
17,238
Previous 16,955
1.67%
Holding current value
$2 Million
Previous $2.34 Million
1.5%
% of portfolio
0.04%
Previous 0.04%
Shares
26 transactions
Others Institutions Holding NBIX
# of Institutions
641Shares Held
95.3MCall Options Held
661KPut Options Held
227K-
Black Rock Inc. New York, NY14.2MShares$1.65 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.17 Billion0.03% of portfolio
-
State Street Corp Boston, MA4.61MShares$534 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.47MShares$286 Million0.6% of portfolio
-
Jpmorgan Chase & CO New York, NY2.36MShares$274 Million0.03% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.1B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...